These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 25015764)
1. Aberrant promoter methylation of the cadherin 13 gene in serum and its relationship with clinicopathological features of prostate cancer. Wang L; Lin YL; Li B; Wang YZ; Li WP; Ma JG J Int Med Res; 2014 Oct; 42(5):1085-92. PubMed ID: 25015764 [TBL] [Abstract][Full Text] [Related]
2. Clinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma. Lin YL; Sun G; Liu XQ; Li WP; Ma JG J Int Med Res; 2011; 39(1):179-86. PubMed ID: 21672320 [TBL] [Abstract][Full Text] [Related]
3. Aberrant Promoter Methylation of Protocadherin8 (PCDH8) in Serum is a Potential Prognostic Marker for Low Gleason Score Prostate Cancer. Lin YL; Li YL; Ma JG Med Sci Monit; 2017 Oct; 23():4895-4900. PubMed ID: 29026066 [TBL] [Abstract][Full Text] [Related]
4. CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients. Widschwendter A; Ivarsson L; Blassnig A; Müller HM; Fiegl H; Wiedemair A; Müller-Holzner E; Goebel G; Marth C; Widschwendter M Int J Cancer; 2004 Mar; 109(2):163-6. PubMed ID: 14750164 [TBL] [Abstract][Full Text] [Related]
5. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Maruyama R; Toyooka S; Toyooka KO; Virmani AK; Zöchbauer-Müller S; Farinas AJ; Minna JD; McConnell J; Frenkel EP; Gazdar AF Clin Cancer Res; 2002 Feb; 8(2):514-9. PubMed ID: 11839671 [TBL] [Abstract][Full Text] [Related]
6. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Henrique R; Ribeiro FR; Fonseca D; Hoque MO; Carvalho AL; Costa VL; Pinto M; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C Clin Cancer Res; 2007 Oct; 13(20):6122-9. PubMed ID: 17947477 [TBL] [Abstract][Full Text] [Related]
7. Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease. Singal R; Ferdinand L; Reis IM; Schlesselman JJ Oncol Rep; 2004 Sep; 12(3):631-7. PubMed ID: 15289848 [TBL] [Abstract][Full Text] [Related]
8. Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation. Padar A; Sathyanarayana UG; Suzuki M; Maruyama R; Hsieh JT; Frenkel EP; Minna JD; Gazdar AF Clin Cancer Res; 2003 Oct; 9(13):4730-4. PubMed ID: 14581343 [TBL] [Abstract][Full Text] [Related]
9. Methylation of RASSF1A and CDH13 genes in individualized chemotherapy for patients with non-small cell lung cancer. Zhai X; Li SJ Asian Pac J Cancer Prev; 2014; 15(12):4925-8. PubMed ID: 24998565 [TBL] [Abstract][Full Text] [Related]
10. Aberrant methylation of the CDH13 (H-cadherin) promoter region in colorectal cancers and adenomas. Toyooka S; Toyooka KO; Harada K; Miyajima K; Makarla P; Sathyanarayana UG; Yin J; Sato F; Shivapurkar N; Meltzer SJ; Gazdar AF Cancer Res; 2002 Jun; 62(12):3382-6. PubMed ID: 12067979 [TBL] [Abstract][Full Text] [Related]
11. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. Hoque MO; Topaloglu O; Begum S; Henrique R; Rosenbaum E; Van Criekinge W; Westra WH; Sidransky D J Clin Oncol; 2005 Sep; 23(27):6569-75. PubMed ID: 16170165 [TBL] [Abstract][Full Text] [Related]
12. Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features. Kim DS; Kim MJ; Lee JY; Kim YZ; Kim EJ; Park JY Cancer; 2007 Dec; 110(12):2785-92. PubMed ID: 17960794 [TBL] [Abstract][Full Text] [Related]
13. Protocadherin-17 promoter methylation in serum-derived DNA is associated with poor prognosis of bladder cancer. Luo ZG; Li ZG; Gui SL; Chi BJ; Ma JG J Int Med Res; 2014 Feb; 42(1):35-41. PubMed ID: 24366498 [TBL] [Abstract][Full Text] [Related]
14. Methylation of the ASC gene promoter is associated with aggressive prostate cancer. Collard RL; Harya NS; Monzon FA; Maier CE; O'Keefe DS Prostate; 2006 May; 66(7):687-95. PubMed ID: 16425203 [TBL] [Abstract][Full Text] [Related]
15. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Toyooka KO; Toyooka S; Virmani AK; Sathyanarayana UG; Euhus DM; Gilcrease M; Minna JD; Gazdar AF Cancer Res; 2001 Jun; 61(11):4556-60. PubMed ID: 11389090 [TBL] [Abstract][Full Text] [Related]
16. Relationship between Methylation of FHIT and CDH13 Gene Promoter Region and Liver Cancer. Tuoya AD; Wang DX; Xing YS; Liu RJ; Hu YX; Zhang MD; Bai TY; Lv XL; Li J; Chang FH Curr Med Sci; 2020 Jun; 40(3):502-509. PubMed ID: 32474857 [TBL] [Abstract][Full Text] [Related]
17. Promoter methylation of protocadherin8 is an independent prognostic factor for biochemical recurrence of early-stage prostate cancer. Niu WB; Gui SL; Lin YL; Fu XL; Ma JG; Li WP Med Sci Monit; 2014 Dec; 20():2584-9. PubMed ID: 25486497 [TBL] [Abstract][Full Text] [Related]
18. Multigene methylation analysis for detection and staging of prostate cancer. Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436 [TBL] [Abstract][Full Text] [Related]
19. Prevalent hyper-methylation of the CDH13 gene promoter in malignant B cell lymphomas. Ogama Y; Ouchida M; Yoshino T; Ito S; Takimoto H; Shiote Y; Ishimaru F; Harada M; Tanimoto M; Shimizu K Int J Oncol; 2004 Sep; 25(3):685-91. PubMed ID: 15289870 [TBL] [Abstract][Full Text] [Related]
20. A Systematic Analysis of the Relationship of CDH13 Promoter Methylation and Breast Cancer Risk and Prognosis. Yang J; Niu H; Huang Y; Yang K PLoS One; 2016; 11(5):e0149185. PubMed ID: 27153114 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]